Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Toename behandelopties voor subgroep met HER2-positief coloncarcinoom
sep 2023 | Maag-darm-leveroncologie